Combined therapy with thioridazine decreases plasma levels of quetiapine in taiwanese schizophrenic patients

Shen Chieh Chang, Mong Liang Lu, Yue Chi Wang, Fang Wei Lin, Shu Huei Huang, Pei Hsin Kuo, Hsiu O. Ho, Tzu Hua Wu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Methods: Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study. QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week. On day 15, blood samples were collected at 12 time points within an 8-hour interval. The authors assayed the plasma levels of QTP with a high-performance liquid chromatography system coupled with ultraviolet detector. Results: Significantly decreased plasma levels of QTP after oral administration were observed in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 hours, and the P values were 0.046, 0.001, and 0.005, respectively. The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002). The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03). Other pharmacokinetic parameters were not significantly different. Conclusions: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP. Although TDZ is switched to QTP, choosing larger doses of QTP for titration may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.

Original languageEnglish
Pages (from-to)345-348
Number of pages4
JournalTherapeutic Drug Monitoring
Volume34
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Thioridazine
Therapeutics
Schizophrenia
Quetiapine Fumarate
Pharmacokinetics
Oral Administration

Keywords

  • Pharmacokinetic interaction
  • Quetiapine
  • Steady-state plasma concentration
  • Therapeutic drug monitoring
  • Thioridazine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Combined therapy with thioridazine decreases plasma levels of quetiapine in taiwanese schizophrenic patients. / Chang, Shen Chieh; Lu, Mong Liang; Wang, Yue Chi; Lin, Fang Wei; Huang, Shu Huei; Kuo, Pei Hsin; Ho, Hsiu O.; Wu, Tzu Hua.

In: Therapeutic Drug Monitoring, Vol. 34, No. 3, 06.2012, p. 345-348.

Research output: Contribution to journalArticle

Chang, Shen Chieh ; Lu, Mong Liang ; Wang, Yue Chi ; Lin, Fang Wei ; Huang, Shu Huei ; Kuo, Pei Hsin ; Ho, Hsiu O. ; Wu, Tzu Hua. / Combined therapy with thioridazine decreases plasma levels of quetiapine in taiwanese schizophrenic patients. In: Therapeutic Drug Monitoring. 2012 ; Vol. 34, No. 3. pp. 345-348.
@article{53bc204dc0494ea485c106f5ce609d09,
title = "Combined therapy with thioridazine decreases plasma levels of quetiapine in taiwanese schizophrenic patients",
abstract = "Background: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Methods: Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study. QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week. On day 15, blood samples were collected at 12 time points within an 8-hour interval. The authors assayed the plasma levels of QTP with a high-performance liquid chromatography system coupled with ultraviolet detector. Results: Significantly decreased plasma levels of QTP after oral administration were observed in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 hours, and the P values were 0.046, 0.001, and 0.005, respectively. The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002). The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03). Other pharmacokinetic parameters were not significantly different. Conclusions: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP. Although TDZ is switched to QTP, choosing larger doses of QTP for titration may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.",
keywords = "Pharmacokinetic interaction, Quetiapine, Steady-state plasma concentration, Therapeutic drug monitoring, Thioridazine",
author = "Chang, {Shen Chieh} and Lu, {Mong Liang} and Wang, {Yue Chi} and Lin, {Fang Wei} and Huang, {Shu Huei} and Kuo, {Pei Hsin} and Ho, {Hsiu O.} and Wu, {Tzu Hua}",
year = "2012",
month = "6",
doi = "10.1097/FTD.0b013e31825479cc",
language = "English",
volume = "34",
pages = "345--348",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Combined therapy with thioridazine decreases plasma levels of quetiapine in taiwanese schizophrenic patients

AU - Chang, Shen Chieh

AU - Lu, Mong Liang

AU - Wang, Yue Chi

AU - Lin, Fang Wei

AU - Huang, Shu Huei

AU - Kuo, Pei Hsin

AU - Ho, Hsiu O.

AU - Wu, Tzu Hua

PY - 2012/6

Y1 - 2012/6

N2 - Background: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Methods: Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study. QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week. On day 15, blood samples were collected at 12 time points within an 8-hour interval. The authors assayed the plasma levels of QTP with a high-performance liquid chromatography system coupled with ultraviolet detector. Results: Significantly decreased plasma levels of QTP after oral administration were observed in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 hours, and the P values were 0.046, 0.001, and 0.005, respectively. The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002). The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03). Other pharmacokinetic parameters were not significantly different. Conclusions: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP. Although TDZ is switched to QTP, choosing larger doses of QTP for titration may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.

AB - Background: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Methods: Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study. QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week. On day 15, blood samples were collected at 12 time points within an 8-hour interval. The authors assayed the plasma levels of QTP with a high-performance liquid chromatography system coupled with ultraviolet detector. Results: Significantly decreased plasma levels of QTP after oral administration were observed in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 hours, and the P values were 0.046, 0.001, and 0.005, respectively. The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002). The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03). Other pharmacokinetic parameters were not significantly different. Conclusions: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP. Although TDZ is switched to QTP, choosing larger doses of QTP for titration may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.

KW - Pharmacokinetic interaction

KW - Quetiapine

KW - Steady-state plasma concentration

KW - Therapeutic drug monitoring

KW - Thioridazine

UR - http://www.scopus.com/inward/record.url?scp=84862094907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862094907&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31825479cc

DO - 10.1097/FTD.0b013e31825479cc

M3 - Article

C2 - 22569350

AN - SCOPUS:84862094907

VL - 34

SP - 345

EP - 348

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -